Trial Profile
A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADAGIO
- Sponsors GrayBug inc.
- 30 Jul 2019 Status changed from recruiting to completed.
- 21 Jan 2019 Top line results presented in a GrayBug media release.
- 05 Mar 2018 According to a GrayBug inc. media release, completion of enrollment of Phase 1 is anticipated by the end of Q2 2018.